Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hospira Inc.

Division of Pfizer Inc.

Latest From Hospira Inc.

Hospira Will Not Be Reheard On Retacrit Biosimilar

Hospira has been frustrated again in long-running litigation concerning its Retacrit biosimilar to Amgen’s Epogen, in a case closely watched by the biopharma industry as it addressed what constitutes a safe harbor for a biosimilar applicant.

Intellectual Property Biosimilars

Celltrion And Pfizer Cement Victory On Infliximab

Celltrion and Pfizer are now two for two in their legal battles with Janssen over US patents shielding the originator's Remicade (infliximab), with a US Court of Appeals once again siding with the biosimilars developers.

Legal Issues Intellectual Property

Amgen Sues Pfizer Over US Pegfilgrastim Biosimilar

Amgen has filed a US patent-infringement lawsuit against Pfizer’s Hospira over its biosimilar pegfilgrastim rival to Neulasta.

United States Biosimilars

Pfizer Delivers On Biosimilars Strategy

Pfizer's biosimilars franchise is well on its way to becoming a blockbuster business, three years after the company launched its first US biosimilar.

Sales & Earnings Biosimilars
See All

Company Information